Wedbush Reaffirms “Outperform” Rating for Dianthus Therapeutics (NASDAQ:DNTH)

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a report issued on Wednesday,Benzinga reports. They presently have a $36.00 price target on the stock. Wedbush’s target price would indicate a potential upside of 69.17% from the company’s current price.

Several other analysts also recently commented on the stock. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Guggenheim reiterated a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $52.14.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH opened at $21.28 on Wednesday. Dianthus Therapeutics has a one year low of $18.13 and a one year high of $33.77. The business’s 50-day moving average price is $22.65 and its two-hundred day moving average price is $24.94. The company has a market capitalization of $629.82 million, a P/E ratio of -8.51 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. On average, equities analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. TCG Crossover Management LLC bought a new stake in Dianthus Therapeutics in the 4th quarter valued at $32,735,000. Braidwell LP lifted its stake in shares of Dianthus Therapeutics by 144.4% in the fourth quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock valued at $26,304,000 after buying an additional 712,902 shares during the period. Vestal Point Capital LP lifted its stake in shares of Dianthus Therapeutics by 172.2% in the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company’s stock valued at $23,435,000 after buying an additional 680,000 shares during the period. State Street Corp grew its position in Dianthus Therapeutics by 101.4% during the third quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after buying an additional 413,425 shares in the last quarter. Finally, Octagon Capital Advisors LP increased its stake in Dianthus Therapeutics by 20.8% during the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock valued at $46,002,000 after acquiring an additional 363,500 shares during the period. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.